HK Stock Market Move | SUNSHINE PHARMA(06887) rose more than 3% after profit increase; expected annual net profit attributable to shareholders is around 270 million yuan; market demand for Osimertinib phosphate has significantly increased.

SUNSHINE PHARMA (06887) rose more than 3% after the report, by the time of publication, it rose 3.01% to HK$43.1, with a turnover of HK$6.4964 million. On the news front, on March 13, SUNSHINE PHARMA announced that for the year ending December 31, 2025, the Group expects to achieve a net profit attributable to equity holders of approximately RMB 270 million, an increase of approximately 228.57% compared to the net loss attributable to equity holders of approximately RMB 210 million in the same period last year. The above-mentioned increase is mainly due to a significant increase in the prevalence of flu during the second half of 2025 compared to the same period last year. The Group's core product, Oseltamivir Phosphate, as the preferred drug for flu prevention and treatment, has seen a substantial increase in market demand due to its precise efficacy and good brand reputation. At the same time, the Group adheres to a diversified market development strategy, continuously strengthens the construction of academic promotion system, optimizes channel layout and terminal coverage, enhances the market penetration rate, brand influence, and commercial value of core products, and other business pipelines also show good performance.